Adzhiflyuks tab Gesves. 20 pc

$3.73

Adzhiflyuks tab Gesves. 20 pc

Quantity:

Description

Composition
Active substance:
1 tablet contains: 400 mg of aluminum hydroxide, magnesium hydroxide 400 mg.
Excipients:
Sucrose 40.0 mg mannitol 282.5 mg 21.0 mg Povidone, 16.0 mg sorbitol, purified water, sodium saccharinate 5.0 mg, isopropanol, colloidal silica, 8.0 mg of peppermint oil leaf 7, 5 mg magnesium stearate 20.0 mg.
Description:
white tablets with the possible presence of single inclusions dark, with mint odor, round, smooth on both sides.
Product form:
Chewable tablets.
10 tablets in a blister Al / PVC.
2 blisters together with instructions for use in a cardboard box.
Contraindications
Expressed renal dysfunction; hypersensitivity to the drug; Children up to age 10 years; hypophosphatemia; sucrose deficit / isomaltase, fructose intolerance, glucose-galactose malabsorption.
Carefully:
Diabetes mellitus, renal impairment, Alzheimer’s disease, pregnancy, lactation.
Indications
Acute gastritis, chronic gastritis with normal or elevated secretion in the acute phase;
Acute duodenitis;
Gastric ulcer and duodenal ulcer in the acute phase;
Erosion of the mucosa of the upper gastrointestinal tract;
Reflux esophagitis;
Hiatal hernia;
Discomfort and pains in epigastrium, heartburn (after excessive consumption of ethanol, nicotine, coffee, medication, errors in the diet).
Interaction with other drugs
It reduces and slows down the absorption of digoxin, indomethacin, salicylates, chlorpromazine, phenytoin, blockers of histamine H2-receptors, beta-blockers; diflunisal, ketoconazole and itraconazole, isoniazid, tetracycline antibiotics and quinolones (ciprofloxacin, norfloxacin, ofloxacin, enoxacin, grepafloksatsina et al.), azithromycin, cefpodoxime, pivampitsillina, rifampicin, anticoagulants, barbiturates (to be applied for 1 hour to 2 hours after ingestion of antacids), fexofenadine, dipyridamole, zalcitabine, chenodeoxycholic and ursodeoxycholic acid, penicillamine and lansoprazole.
M-holinoblokatory, slowing gastric emptying, enhance and prolong the action of the drug.
In an application with quinidine may increase serum concentrations of quinidine and development quinidine overdose.
When combined with the use of polystyrene sulfonate (kayeksalatom) may reduce the effectiveness of the potassium binding and the development of metabolic alkalosis in patients with renal failure and intestinal obstruction.
When combined with citrate may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
Overdose
Symptoms include diarrhea, abdominal pain, vomiting.
Treatment: replenishing fluid loss, forced diuresis. In renal insufficiency – hemodialysis.
pharmachologic effect
Pharmacological group:
Antacid.
Pharmacodynamics:
Combined means whose action is due to its constituent components: providing the antacid, adsorbent, enveloping effect. Neutralize free hydrochloric acid in the stomach reduces the pepsin activity, gastric juice, reduces the influence of disturbing factors on the gastric mucosa. It does not cause secondary gastric acid hypersecretion. Practically not absorbed from the gastrointestinal tract. Evenly distributed over the gastric mucosa and provides a prolonged gastroprotektsiyu. The therapeutic effect is manifested after 3-5 minutes and lasts an average of 70 minutes.
Pharmacokinetics:
Absorption – low. Subject to the proper dosage regimen and duration of treatment, the drug is practically not absorbed from the gastrointestinal tract does not violate the electrolyte balance and creates the danger of alkalosis or other metabolic disorders.
Pregnancy and breast-feeding
Use during pregnancy is possible if the potential benefit justifies the potential risk to the fetus.
When used according to the recommendations of magnesium hydroxide and aluminum salts absorption is limited and the drug found compatible with breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
From the digestive system: constipation, diarrhea, nausea, vomiting, change in taste.
Immune system: hypersensitivity reactions (pruritus, urticaria, angioneurotic edema, anaphylactic reactions).
Miscellaneous: prolonged administration of high doses – hypophosphataemia, hypocalcaemia, hypercalciuria, osteomalacia, osteoporosis, gipermagniemiya, giperalyuminiemiya, encephalopathy, nephrocalcinosis, renal function.
In patients with concomitant renal failure – thirst, blood pressure, hyporeflexia.
special instructions
Observe the 2-hour interval between doses Adzhiflyuks drug and other medicaments.
In the application should provide a sufficient dietary intake of phosphorus salts.
Before the drug Adzhiflyuks tablets with diabetes need to consider sugar content per tablet – 40.0 mg of sucrose, which is less than 1 grain units (BU).
Effects on ability to drive and use machines.
It does not affect the ability when driving and busy with other potentially hazardous activities that require increased attention and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside, the tablet must be chewed or kept in the mouth until complete dissolution.
Adults drug prescribed 2-3 tablets 1-2 hours after meals and at bedtime, gastric ulcer – 30 minutes before meals; if necessary, a single dose of 3-4 tablets. After a therapeutic effect – maintenance therapy: 1 tablet 3 times a day for 2-3 months.
Children from 10 years: 1 tablet every 1-2 hours after eating and at night, with stomach ulcers – 30 minutes before meals.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Adzhio

There are no reviews yet.

Add your review